These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22219363)

  • 1. Enhanced HIV-1 neutralization by antibody heteroligation.
    Mouquet H; Warncke M; Scheid JF; Seaman MS; Nussenzweig MC
    Proc Natl Acad Sci U S A; 2012 Jan; 109(3):875-80. PubMed ID: 22219363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.
    Song R; Pace C; Seaman MS; Fang Q; Sun M; Andrews CD; Wu A; Padte NN; Ho DD
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):365-373. PubMed ID: 27792681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.
    Chakrabarti BK; Walker LM; Guenaga JF; Ghobbeh A; Poignard P; Burton DR; Wyatt RT
    J Virol; 2011 Aug; 85(16):8217-26. PubMed ID: 21653673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS; Gnanapragasam PN; Galimidi RP; Foglesong CP; West AP; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7385-90. PubMed ID: 19372381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
    Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
    Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
    Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
    J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Grundner C; Li Y; Louder M; Mascola J; Yang X; Sodroski J; Wyatt R
    Virology; 2005 Jan; 331(1):33-46. PubMed ID: 15582651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.
    Louis JM; Aniana A; Lohith K; Sayer JM; Roche J; Bewley CA; Clore GM
    PLoS One; 2014; 9(8):e104683. PubMed ID: 25105806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
    Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
    Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
    Burrer R; Haessig-Einius S; Aubertin AM; Moog C
    Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.
    Wang P; Yang X
    J Virol; 2010 Jul; 84(14):7114-23. PubMed ID: 20463081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.
    Durham ND; Yewdall AW; Chen P; Lee R; Zony C; Robinson JE; Chen BK
    J Virol; 2012 Jul; 86(14):7484-95. PubMed ID: 22553332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.
    Montgomery DL; Wang YJ; Hrin R; Luftig M; Su B; Miller MD; Wang F; Haytko P; Huang L; Vitelli S; Condra J; Liu X; Hampton R; Carfi A; Pessi A; Bianchi E; Joyce J; Lloyd C; Geleziunas R; Bramhill D; King VM; Finnefrock AC; Strohl W; An Z
    MAbs; 2009; 1(5):462-74. PubMed ID: 20065653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.